JAJames Arthos

James Arthos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


James Arthos has a total of 21 co-authors. Here are the top co-authors by number of shared publications:

  • Aftab A. Ansari

    Department of Pathology, Emory University School of Medicine, Atlanta, GA, 30322, USA

    2 shared publications
  • Anthony S. Fauci

    Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA

    2 shared publications
  • Claudia Cicala

    Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA

    2 shared publications
  • Fatima Nawaz

    Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA

    2 shared publications
  • Francois Villinger

    New Iberia Research Center, University of Louisiana at Lafayette, New Iberia, LA, 70560, USA

    2 shared publications
  • Alia Sajani

    Laboratory of Immunoregulation, National Institutes of Allergy & Infectious Diseases, National Institutes of Health, Bethesda, MD, 20814, USA

    1 shared publication

Latest Publications

  • Open Access

    MAdCAM costimulation through Integrin-α4β7 promotes HIV replication

    by Fatima Nawaz, Livia R. Goes, Jocelyn C. Ray, Ronke Olowojesiku, Alia Sajani, Aftab A. Ansari, Ian Perrone, Joseph Hiatt, Donald Van Ryk, Danlan Wei, et al.


  • Open Access

    The Role of Integrin α4β7 in HIV Pathogenesis and Treatment

    by James Arthos, Claudia Cicala, Fatima Nawaz, Siddappa N. Byrareddy, Francois Villinger, Philip J. Santangelo, Aftab A. Ansari, Anthony S. Fauci

    Purpose of Review Acute HIV infection is characterized by high-level viral replication throughout the body’s lymphoid system, particularly in gut-associated lymphoid tissues resulting in damage to structural components of gut tissue. This damage is irreversible and believed to contribute to the development of immune deficiencies. Antiretroviral therapy (ART) does not restore gut structure and function. Studies in macaques point to an alternative treatment strategy that may ameliorate gut damage. Integrin α4β7 mediates the homing of lymphocytes to gut tissues. Vedolizumab, a monoclonal antibody (mAb) antagonist of α4β7, has demonstrated efficacy and has been approved for the treatment of inflammatory bowel disease in humans. Here, we describe our current knowledge, and the gaps in our understanding, of the role of α4β7 in HIV pathogenesis and treatment. Recent Findings When administered to macaques prior to infection, a nonhuman primate analogue of vedolizumab prevents transmission of SIV. In combination with ART, this mAb facilitates durable virologic control following treatment interruption. Summary Targeting α4β7 represents a novel therapeutic approach to prevent and treat HIV infection.